We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Immunohistochemistry as Effective as DNA Hybridization for Detecting ALK Rearrangement in Lung Cancer Patients

By LabMedica International staff writers
Posted on 08 Jul 2013
A team of Chinese researchers demonstrated that immunohistochemistry (IHC) provided a reliable and cost-effective diagnostic approach in routine pathologic laboratories for the identification of patients with non-small-cell lung cancer (NSCLC), in particular adenocarcinomas (ADCs), suitable for ALK-targeted therapy.

The ALK gene can be oncogenic in three ways: by forming a fusion gene with any of several other genes, by gaining additional gene copies, or with mutations of the actual DNA code for the gene itself. More...
The EML4-ALK (echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase) fusion gene is responsible for approximately 3%–5% of cases of NSCLC. The standard tests used to detect this gene in tumor samples is fluorescence in situ hybridization (FISH), and Reverse Transcriptase-PCR (RT-PCR). The FISH technique utilizes a DNA probe labeled with a fluorescent dye that is hybridized with target DNA, usually chromosome preparations on a microscopic slide. It is used to precisely map genes to a specific region of a chromosome in prepared karyotype, or can enumerate chromosomes, or can detect chromosomal deletions, translocations, or gene amplifications in cancer cells.

As IHC is a less complex and less costly technology than FISH, investigators at the Chinese University of Hong Kong SAR (China) evaluated its practical usefulness for detection of ALK rearrangement in NSCLC ADCs. They tested 373 lung ADCs for ALK rearrangement by IHC and FISH. Multiplex RT-PCR was performed to confirm the fusion variants.

Results showed that 22 of 373 lung ADCs (5.9%) were positive for ALK immunoreactivity. ALK-positive tumor cells demonstrated strong and diffused granular staining in the cytoplasm. All the ALK IHC-positive cases were confirmed to harbor ALK rearrangement, by either FISH, or RT-PCR. Two cases that were positive for ALK protein expression by IHC, but negative by FISH were shown to harbor EML4-ALK variant 1 by RT-PCR. None of the ALK IHC-negative cases was FISH-positive.

These results allowed the investigators to conclude that, "IHC can effectively detect ALK rearrangement in lung cancer. It might provide a reliable and cost-effective diagnostic approach in routine pathologic laboratories for the identification of suitable candidates for ALK-targeted therapy."

The study was published in the July 2013 issue of the Journal of Thoracic Oncology.

Related Links:
Chinese University of Hong Kong



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
Automated Coagulation Analyzer
Hemolumi H6
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.